Ask AI
ProCE Banner Activity

Assessing UDCA Intolerance and Response in PBC: First-line Treatment Questions

Clinical Thought

As first-line treatment for primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA) is usually well tolerated, but some patients experience intolerance. Learn how to manage intolerance and when to assess for treatment response and incorporate second-line therapy based on recent changes in the treatment paradigm.

Released: March 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity is intended for physicians, including hepatologists and gastroenterologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals involved in the care of patients with PBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop personalized management plans for patients with PBC based on individual risk, comorbidities, and symptoms

Disclosure

Primary Author

Sonal Kumar, MD, MPH: consultant/advisor/speaker: Boehringer Ingelheim, Gilead, GSK, Ipsen, Madrigal, Novo Nordisk.